Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: OpenEvidence does not list a price
Free plan
OpenEvidence
Only OpenEvidence has one
Higher rating
OpenEvidence
4.4 against 4.3
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
OpenEvidence
Tempus AI
Our rating
4.4Better
4.3
Starts at
Free
Not listed
Free plan
YesBetter
No
Category
Healthcare AI
Healthcare AI
Plans
Free
See pricing
Key features
Point-of-care clinical answers grounded in peer-reviewed literature with citations
760,000 registered US physicians, roughly 40% of all US doctors
Approximately 18 million clinical consultations handled monthly
Free for verified physicians, monetized through pharmaceutical advertising
$12B valuation after a $250M Series D in January 2026
Machine learning applied to genomic and clinical data for precision treatment matching
One of the largest connected libraries of clinical and molecular data
Publicly traded on Nasdaq under the ticker TEM
Q1 2026 revenue of $348.1M, up 36.1% year over year
2026 revenue guidance raised to $1.59-$1.60 billion
Pros
Free access for physicians removes cost as a barrier to point-of-care use
Citations grounded in peer-reviewed literature build clinical trust
Extraordinarily fast physician adoption validates genuine day-to-day utility
Publicly reported financials give unusual transparency into scale and growth
Massive, growing data library strengthens precision-matching over time
Strong, consistent revenue growth across both diagnostics and data segments
Cons
Monetized through pharmaceutical advertising, which some clinicians may view with caution
Built for point-of-care physician use, not a full clinical documentation platform
Extremely fast valuation growth invites scrutiny over long-term sustainability
Pricing runs through insurance billing and enterprise agreements, not published rates
Built specifically for precision medicine and oncology, a narrower clinical scope
Best suited to institutions already positioned to act on genomic testing results
Company
OpenEvidence, founded 2022
Tempus AI, founded 2015
Prices come from each vendor's pricing page, last checked 20260715. Check the vendor before you buy.
FAQ
Questions people ask
Is OpenEvidence better than Tempus AI?
In our reviews OpenEvidence scores 4.4 and Tempus AI scores 4.3. The better pick depends on the job. OpenEvidence: Used by 40% of US physicians, doubling its valuation to $12B in under a year. Tempus AI: Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue.
OpenEvidence
Tempus AI
